Mechanisms of BRCA1 tumor suppression - PubMed (original) (raw)
Review
Mechanisms of BRCA1 tumor suppression
Daniel P Silver et al. Cancer Discov. 2012 Aug.
Abstract
The p220 BRCA1 tumor suppressor protein has been implicated in multiple biochemical and biologic functions since its molecular cloning 18 years ago. Here, we discuss those functions most relevant for its tumor-suppressing activities with an emphasis on new findings. In particular, this review focuses on what is known of the activities of those BRCA1-binding partners that have tumor suppressor functions, on the reversion of mutant BRCA1 alleles concomitant with therapy resistance, on insights gained from studies of BRCA1 structure-function relationships, recent findings from animal models, and the potential role of BRCA1 in some nonhereditary tumors. From this information, a more detailed and refined picture of BRCA1 tumor suppression is beginning to emerge. Although key mysteries remain--such as why BRCA1 tumor suppression is focused on carcinomas of the breast and ovary--the pace of discovery is increasing.
Significance: BRCA1 functions as a clinically important classical tumor suppressor in hereditary breast and ovarian cancer; here, we review progress in understanding how BRCA1 operates to suppress tumor formation.
Figures
Figure
The domain structure of BRCA1 is shown, with the RING domain in blue, the tandem nuclear localization signals in yellow, the Coiled-coil domain in green, and the two BRCT domains in red. Amino acid locations of mutations referred to in the review are as shown.
Similar articles
- The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients.
Elledge SJ, Amon A. Elledge SJ, et al. Cancer Cell. 2002 Mar;1(2):129-32. doi: 10.1016/s1535-6108(02)00041-7. Cancer Cell. 2002. PMID: 12086871 No abstract available. - A structural bioinformatics approach to explore the interactions of P53 and BRCA1 gene products on ovarian and breast cancer.
Parija S, Kumar A. Parija S, et al. Int J Bioinform Res Appl. 2011;7(1):1-14. doi: 10.1504/IJBRA.2011.039166. Int J Bioinform Res Appl. 2011. PMID: 21441093 - BRCA1 in breast and ovarian cancer predisposition.
Billack B, Monteiro AN. Billack B, et al. Cancer Lett. 2005 Sep 8;227(1):1-7. doi: 10.1016/j.canlet.2004.11.006. Epub 2004 Dec 13. Cancer Lett. 2005. PMID: 16051027 Review. - Opportunities and hurdles in the treatment of BRCA1-related breast cancer.
Drost R, Jonkers J. Drost R, et al. Oncogene. 2014 Jul 17;33(29):3753-63. doi: 10.1038/onc.2013.329. Epub 2013 Aug 19. Oncogene. 2014. PMID: 23955079 Review. - BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer.
Sedic M, Kuperwasser C. Sedic M, et al. Cell Cycle. 2016;15(5):621-7. doi: 10.1080/15384101.2016.1141841. Cell Cycle. 2016. PMID: 26822887 Free PMC article. Review.
Cited by
- DOT1L-mediated RAP80 methylation promotes BRCA1 recruitment to elicit DNA repair.
Tang H, Lu YF, Zeng R, Liu C, Shu Y, Wu Y, Su J, Di L, Qian J, Zhang J, Tian Y, Lu X, Pei XH, Zhu Q, Zhu WG. Tang H, et al. Proc Natl Acad Sci U S A. 2024 Aug 27;121(35):e2320804121. doi: 10.1073/pnas.2320804121. Epub 2024 Aug 22. Proc Natl Acad Sci U S A. 2024. PMID: 39172790 - R-loop functions in _Brca1_-associated mammary tumorigenesis.
Chiang HC, Qi L, Mitra P, Huang Y, Hu Y, Li R. Chiang HC, et al. Proc Natl Acad Sci U S A. 2024 Aug 13;121(33):e2403600121. doi: 10.1073/pnas.2403600121. Epub 2024 Aug 8. Proc Natl Acad Sci U S A. 2024. PMID: 39116124 - Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options.
Gao H, Xi Z, Dai J, Xue J, Guan X, Zhao L, Chen Z, Xing F. Gao H, et al. Mol Cancer. 2024 May 3;23(1):88. doi: 10.1186/s12943-024-02005-y. Mol Cancer. 2024. PMID: 38702734 Free PMC article. Review. - HJURP is recruited to double-strand break sites and facilitates DNA repair by promoting chromatin reorganization.
Serafim RB, Cardoso C, Storti CB, da Silva P, Qi H, Parasuram R, Navegante G, Peron JPS, Silva WA Jr, Espreafico EM, Paçó-Larson ML, Price BD, Valente V. Serafim RB, et al. Oncogene. 2024 Mar;43(11):804-820. doi: 10.1038/s41388-024-02937-1. Epub 2024 Jan 26. Oncogene. 2024. PMID: 38279062 - Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients.
Saldajeno DP, Kawaoka S, Masuda N, Tanaka S, Bando H, Nishimura T, Kadoya T, Yamanaka T, Imoto S, Velaga RM, Tamura N, Aruga T, Ikeda K, Fukui Y, Maeshima Y, Takada M, Suzuki E, Ueno T, Ogawa S, Haga H, Ohno S, Morita S, Kawaguchi K, Toi M. Saldajeno DP, et al. Br J Cancer. 2024 Apr;130(6):1023-1035. doi: 10.1038/s41416-023-02527-0. Epub 2024 Jan 18. Br J Cancer. 2024. PMID: 38238427
References
- Bochar DA, Wang L, Beniya H, Kinev A, Xue Y, Lane WS, et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell. 2000;102:257–265. - PubMed
- Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell. 2007;11:103–105. - PubMed
- Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Molecular Cell. 2006;22:719–729. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA089393/CA/NCI NIH HHS/United States
- P01 CA080111/CA/NCI NIH HHS/United States
- P50 CA089393/CA/NCI NIH HHS/United States
- R01 CA136512/CA/NCI NIH HHS/United States
- K08 CA082572/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous